bluuebunny/crossref_metadata_2025_split huggingface dataset:
A structural model of job resources, organisational and individual strengths use and work engagement
Authors: Botha Cheri , Mostert Karina 
Published: February 2014

Orientation: Organisations will not be able to maintain a competitive advantage by merely focusing on the development of their employees’ weaknesses. Employees should also be provided with sufficient job resources and opportunities to develop and use their strengths, as this could lead to work engagement.Research purpose: To test a structural model of job resources, perceived organisational support for strengths use, proactive behaviour towards strengths use and work engagement amongst South African employees.Motivation for the study: To gain more knowledge and a better understanding of the outcomes of following an organisational and individual strength-based approach focused on the use of strengths within the South African context.Research approach, design and method: A quantitative approach with cross-sectional research design was used. An availability sample (N = 401) of employees from various occupational groups in South Africa was used. Structural equation modelling was used to test the model.Main findings: The results indicated that perceived organisational support for strengths use and employees’ proactive behaviour towards strengths use were strongly and positively associated with work engagement in the structural model.Practical/managerial implications: Knowledge of using strengths from an organisational and individual perspective could assist organisations in gaining a better understanding of the relationship with work engagement.Contribution/value-add: This study adds to the limited research on using strengths from both an organisational and individual perspective and possible outcomes within the South African context.
Effect of incorporation of silane in the bonding agent on the repair potential of machinable esthetic blocks
Authors: Zaghloul Hanaa , Elkassas Dina Wafik , Haridy Mohamed Fouad 
Published: February 2014

ABSTRACT
Objective: To investigate the repair potential of CAD/CAM (computer-aided design/computer-aided manufacturing) ceramic and composite blocks using a silane-containing bonding agent with different repair protocols. Materials and Methods: Twenty-four discs were constructed from CAD/CAM ceramic and composite blocks. The discs were divided into six groups according to surface pre-treatment employed; GI: Diamond stone roughening (SR), GII: SR+ silanization (SR+S), GIII: Hydrofluoric acid etching (HF), GIV: HF+ silanization (HF+S), GV: Silica coating (SC), GVI: SC+ silanization (SC+S). Silane-containing bonding agent (Single Bond Universal adhesive, 3M ESPE) was applied to the pre-treated discs. Prior to light curing, irises were cut from tygon tubes (internal diameter = 0.8 mm and height = 0.5 mm) and mounted on each treated surface. Nanofilled resin composite (Filtek Z350XT, 3M ESPE) was packed into the cylinder lumen and light-cured (n = 10). The specimens were subjected to microshear bond strength testing (μ-SBS) using universal testing machine. Failure modes of the fractured specimens were analyzed using field emission scanning electron microscope (FESEM). Eight representative discs were prepared to analyze the effect of surface treatments on surface topography using FESEM. μ-SBS results were analyzed using ANOVA and Tukeys post-hoc test. Results: Three-way ANOVA results showed that the materials, surface pre-treatment protocols, and silanization step had a statistically significant effect on the mean μ-SBS values at P ≤ 0.001. For ceramic discs, the groups were ranked; GIV (24.45 ± 7.35)> GVI ((20.18 ± 2.84)> GV (7.14 ± 14)= GII (6.72 ± 1.91)=GI (6.34 ± 2.21)=GIII (5.72 ± 2.18). For composite discs, groups were ranked; GI (24.98 ± 7.69)=GVI (24.84 ± 7.00) >GII (15.85 ± 5.29) =GV (14.65 ± 4.5)= GIV (14.24 ± 2.95)≥ GIII ((9.37 ± 2.78). Conclusion: The additional silanization step cannot be omitted if the repair protocol comprises of either hydrofluoric acid etching or silica coating for both CAD/CAM esthetic restorative materials. However, this step can be suppressed by using silane-containing adhesive with diamond stone roughened repair protocol.
Surface and mineral changes of enamel with different remineralizing agents in conjunction with carbon-dioxide laser
Authors: Mohan Ajit George , Ebenezar A. V. Rajesh , Ghani Mohamed Fayas , Martina Leena , Narayanan Ashwin , Mony Bejoy 
Published: February 2014

ABSTRACT
Aim: The aim of this study was to evaluate the surface/mineral changes on enamel before and after the application of acidulated phosphate fluoride (APF) gel, fluoride enhanced hydroxyapatite gel and propolis in conjunction with carbon-dioxide (CO2) laser. Materials and Methods: Crowns of 40 human maxillary central incisors were collected and were divided into four groups of 10 each: Topical fluoride application only, topical fluoride application followed by CO2 laser irradiation, CO2 laser irradiation followed by topical fluoride application and CO2 laser irradiation before and after topical fluoride application. The 10 crowns in each group was again sectioned into four equal parts of mesio-incisal, disto-incisal, mesio-cervical and disto-cervical sections rendering 40 samples in each group. Each group was again subdivided into four subgroups: Subgroup C - untreated enamel surface (control). Subgroup A - APF gel application, subgroup R - fluoride enhanced hydroxyapatite gel application and subgroup P - propolis application. The surface morphology of the test samples were analyzed by scanning electron microscopy and mineral changes by energy dispersion X-ray spectrophotometer. Results: Total mineral content is maximum in Group 4A (CO2 laser irradiation before and after APF gel application) and calcium/phosphate ratio is highest in Group 4R (CO2 laser irradiation before and after Remin-Pro application). Group 2A (APF gel application followed by CO2 laser irradiation) has the maximum fluoride retention. Conclusion: Laser irradiation of enamel through a topically applied APF gel is effective in the prophylaxis and management of dental caries.
Acceptable Cardiac Safety Profile of Neoadjuvant 5-Fluorouracil, Epirubicin, Cyclophosphamide and Celecoxib (FEC-C) for Breast Cancer: A Subanalysis of Biomarkers for Cardiac Injury
Authors: Chow Louis WC , Loo Wings TY , Yip Adrian YS , Ng Elizabeth LY 
Published: February 2014

Purposes This substudy aimed to examine the changes in biomarkers for cardiac injury in patients who received neoadjuvant 5-fluorouracil, epirubicin, cyclophosphamide with concurrent celecoxib (FEC-C). Methods Thirty-four female patients with histologically confirmed locally advanced breast cancer preoperatively received 3 cycles of FEC-C (500 mg/m2, 75 mg/m2, 500 mg/m2) with concurrent celecoxib (400 mg bid). Blood samples were drawn from patients on day (D) 0, D3, D21, D42, and D63 (end of therapy), and the serum levels of lactate dehydrogenase (LDH) and plasma levels of cardiac troponin I (cTnI) and N-terminal prohormone brain-type natriuretic peptide (NT-proBNP) were measured with commercially available test kits. Results All patients tolerated this regimen well. Neither life-threatening toxicity nor clinical symptoms of cardiac damage were observed. Serum LDH increased significantly from baseline after 3 cycles of FEC-C (p<0.0001), but the change was possibly brought about by chemotherapy-induced liver derangement. However, NT-proBNP decreased significantly (p=0.009), while cTnI increased nonsignificantly (p=0.078) after 3 cycles of FEC-C compared to baseline, although this increase was still regarded as normal. Conclusions Short-term use of the FEC-C regimen has proven to be effective in locally advanced breast cancer, with an acceptable cardiac safety profile.
Overview of the Publications from the Anthroposophic Medicine Outcomes Study (AMOS): A Whole System Evaluation Study
Authors: Hamre Harald Johan , Kiene Helmut , Ziegler Renatus , Tröger Wilfried , Meinecke Christoph , Schnürer Christof , Vögler Hendrik , Glockmann Anja , Kienle Gunver Sophia 
Published: February 2014

Anthroposophic medicine is a physician-provided complementary therapy system that was founded by Rudolf Steiner and Ita Wegman. Anthroposophic therapy includes special medicinal products, artistic therapies, eurythmy movement exercises, and special physical therapies. The Anthroposophic Medicine Outcomes Study (AMOS) was a prospective observational multicenter study of 1631 outpatients starting anthroposophic therapy for anxiety disorders, asthma, attention deficit hyperactivity disorder, depression, low back pain, migraine, and other chronic indications under routine conditions in Germany. AMOS incorporated two features proposed for the evaluation of integrative therapy systems: (1) a sequential approach, starting with the whole therapy system (use, safety, outcomes, perceived benefit), addressing comparative effectiveness and proceeding to the major system components (physician counseling, anthroposophic medicinal products, art therapy, eurythmy therapy, rhythmical massage therapy) and (2) a mix of different research methods to build an information synthesis, including pre-post analyses, prospective comparative analyses, economic analyses, and safety analyses of individual patient data. AMOS fostered two methodological innovations for the analysis of singlearm therapy studies (combined bias suppression, systematic outcome comparison with corresponding cohorts in other studies) and the first depression cost analysis worldwide comparing primary care patients treated for depression vs depressed patients treated for another disorder vs nondepressed patients. A total of 21 peer-reviewed publications from AMOS have resulted. This article provides an overview of the main research questions, methods, and findings from these publications: anthroposophic treatment was safe and was associated with clinically relevant improvements in symptoms and quality of life without cost increase; improvements were found in all age, diagnosis, and therapy modality groups and were retained at 48-month follow-up; nonrespondent bias, natural recovery, regression to the mean, and adjunctive therapies together could explain a maximum of 37% of the improvement.
Health Care Resource Use for Modern First-Line Treatments in Metastatic Renal Cell Carcinoma
Authors: Shah Neil J. , Shinde Reshma , Moore Kristin J. , Sainski-Nguyen Amy , Le Lisa B. , Cao Feng , Song Rui , Singhal Puneet , Motzer Robert J. 
Published: July 2024

ImportanceImmuno-oncology agents have changed the treatment paradigm for metastatic renal cell carcinoma (mRCC). Such therapies improve survival but can impose considerable health care resource use (HCRU) and associated costs, necessitating their examination.ObjectiveTo compare HCRU, costs, and clinical outcomes among patients receiving first-line pembrolizumab plus axitinib (P+A) or ipilimumab plus nivolumab (I+N).Design, Setting, and ParticipantsThis retrospective cohort study used data from an administrative claims database on patients with mRCC receiving first-line P+A or I+N that was initiated between January 2018 and May 2020. Data were analyzed from February 2021 to July 2022.ExposureFirst-line P+A or I+N.Main Outcome and MeasuresHCRU and costs during the first 90 days, full first-line treatment, and full follow-up periods were assessed. Using Kaplan-Meier analysis, time on treatment, overall survival, time to first emergency department (ED) visit, and time to first inpatient stay were compared.ResultsAmong 507 patients, there were 126 patients receiving P+A (91 male [72.2%]; mean [SD] age, 67.93 [9.66] y) and 381 patients receiving I+N (271 male [71.1%]; mean [SD] age, 66.52 [9.94] years). The median time on treatment was longer for the P+A compared with I+N group (12.4 months [95% CI, 8.40 months to not estimable] vs 4.1 months [95% CI, 3.07 to 5.30 months]; P &amp;lt; .001). The median time to first ED visit was longer for the P+A than I+N group (7.2 months [95% CI 3.9 to 11.1 months ] vs 3.3 months [95% CI, 2.6 to 3.9 months]; P = .005), as was time to first inpatient stay (9.0 months [95% CI 6.5 months to not estimable] vs 5.6 months [95% CI, 3.9 to 7.9 months]; P = .02). During the first 90 days, a lower proportion of the P+A than N+I group had ED visits (43 patients [34.1%] vs 182 patients [47.8%] and inpatient stays (24 patients [19.1%) vs144 patients [37.8%]; P &amp;lt; .001). During full follow-up, mean total adjusted costs were similar for P+A and I+N groups, but adjusted 12-month estimated total costs were higher for P+A than I+N groups ($325 574 vs $ 263 803; P = .03).Conclusions and RelevanceIn this study, treatment with P+A was associated with longer time on treatment, time to first ED visit, and inpatient stay, while 12-month estimated costs were higher for the P+A group. This is among the first clinical studies to evaluate economic burden associated with modern treatments for mRCC.
Bintrafusp Alfa for Recurrent or Metastatic Cervical Cancer After Platinum Failure
Authors: Birrer Michael , Li Guiling , Yunokawa Mayu , Lee Jung-Yun , Kim Byoung Gie , Oppermann Christina Pimentel , Zhou Qi , Nishio Shin , Okamoto Aikou , Wu Xiaohua , Mileshkin Linda , Oaknin Ana , Ray-Coquard Isabelle , Hasegawa Kosei , Jehl Genevieve , Vugmeyster Yulia , Zhang Sen , Bajars Marcis , Yonemori Kan 
Published: July 2024

ImportanceCervical cancer is a common and lethal cancer worldwide. Bintrafusp alfa is a first-in-class bifunctional fusion protein composed of the extracellular domain of the human transforming growth factor β receptor II (or transforming growth factor β trap) fused via a flexible linker to the C-terminus of each heavy chain of an immunoglobulin G1 antibody blocking programmed cell death 1 ligand 1.ObjectiveTo evaluate the safety and response rates of bintrafusp alfa in patients with recurrent or metastatic cervical cancer.Design, Setting, and ParticipantsThis phase 2 nonrandomized controlled trial evaluated bintrafusp alfa monotherapy in patients with recurrent or metastatic cervical cancer with disease progression during or after platinum-based chemotherapy. Data were collected from March 2020 to February 2022.InterventionPatients received bintrafusp alfa, 1200 mg, intravenously once every 2 weeks.Main Outcomes and MeasuresThe primary end point was confirmed objective response rate per Response Evaluation Criteria in Solid Tumors version 1.1 by an independent review committee.ResultsAt data cutoff, 146 of 203 screened patients received 1 or more doses of bintrafusp alfa; of these, the median (range) age was 53 (24-79) years. The study met its primary end point of a 95% CI above the objective response rate benchmark of 15%, with a confirmed objective response rate of 21.9% (95% CI, 15.5-29.5) per the independent review committee. Of these patients, 19 (59.4%) had a durable response of 6 months or more. At data cutoff, responses were ongoing in 13 of 32 responders (40.6%). The most common treatment-related adverse events were anemia (25 [17.1%]), rash (21 [14.4%]), hypothyroidism (15 [10.3%]), and pruritus (15 [10.3%]). Any-cause adverse events of special interest included anemia (82[56.2%]), bleeding events (81 [55.5%]), and immune-related adverse events (49 [33.6%]).Conclusions and RelevanceThis phase 2 nonrandomized controlled trial of bintrafusp alfa met its primary end point, which may support the potential of a bispecific therapy targeting transforming growth factor β and programmed cell death 1 ligand 1 in patients with recurrent or metastatic cervical cancer.Trial RegistrationClinicalTrials.gov Identifier: NCT04246489
Clinical utility of diffusion MRI‐derived measures of cortical microstructure in a real‐world memory clinic setting
Authors: Torso Mario , Fumagalli Giorgio , Ridgway Gerard R. , Contarino Valeria Elisa , Hardingham Ian , Scarpini Elio , Galimberti Daniela , Chance Steven A. , Arighi Andrea 
Published: July 2024

AbstractObjectiveTo investigate cortical microstructural measures from diffusion MRI as “neurodegeneration” markers that could improve prognostic accuracy in mild cognitive impairment (MCI).MethodsThe prognostic power of Amyloid/Tau/Neurodegeneration (ATN) biomarkers to predict progression from MCI to AD or non‐AD dementia was investigated. Ninety patients underwent clinical evaluation (follow‐up interval 32 ± 18 months), lumbar puncture, and MRI. Participants were grouped by clinical stage and cerebrospinal fluid Amyloid and Tau status.T1‐structural and diffusion MRI scans were analyzed to calculate diffusion metrics related to cortical columnar structure (AngleR, ParlPD, PerpPD+), cortical mean diffusivity, and fractional anisotropy. Statistical tests were corrected for multiple comparisons. Prognostic power was assessed using receiver operating characteristic (ROC) analysis and related indices.ResultsA progressive increase of whole‐brain cortical diffusion values was observed along the AD continuum, with all A+ groups showing significantly higher AngleR than A−T−.Investigating clinical progression to dementia, the AT biomarkers together showed good positive predictive value (with 90.91% of MCI A+T+ converting to dementia) but poor negative predictive value (with 40% of MCI A−T− progressing to a mix of AD and non‐AD dementias). Adding whole‐brain AngleR as an N marker, produced good differentiation between stable and converting MCI A−T− patients (0.8 area under ROC curve) and substantially improved negative predictive value (+21.25%).InterpretationResults support the clinical utility of cortical microstructure to aid prognosis, especially in A−T− patients. Further work will investigate other complexities of the real‐world clinical setting, including A−T+ groups. Diffusion MRI measures of neurodegeneration may complement fluid AT markers to support clinical decision‐making.
Automated Synthesis of DNA Nanostructures
Authors: Islas Patricia , Platnich Casey M. , Gidi Yasser , Karimi Ryan , Ginot Lorianne , Saliba Daniel , Luo Xin , Cosa Gonzalo , Sleiman Hanadi F. 
Published: July 2024

AbstractDNA nanotechnology has revolutionized the ability to position matter at the nanoscale, but the preparation of DNA‐based architectures remains laborious. To facilitate the formation of custom structures, a fully automated method is reported to produce sequence‐ and size‐defined DNA nanotubes. By programming the sequential addition of desired building blocks, rigid DX‐tile‐based DNA nanotubes and flexible wireframe DNA structures are attained, where the total number of possible constructs increases as a power function of the number of different units available. Using single‐molecule fluorescence imaging, the kinetics and yield of each synthetic step can be quantitatively determined, revealing differences in self‐assembly dynamics as the nanotube is built up from the solid support and providing new insights into DNA self‐assembly. The exploitation of automation for both assembly and analysis (through an ad‐hoc developed K‐means clustering algorithm) facilitates a workflow wherein the synthesis parameters may be iteratively improved upon, demonstrating how a single‐molecule “assembly‐analysis‐optimization” sequence can be used to generate complex, noncovalent materials in good yield. The presented synthetic strategy is generalizable, making use of equipment already available in most standard laboratories and represents the first fully automated supramolecular assembly on a solid support.
AI‐Assisted Self‐Powered Vehicle‐Road Integrated Electronics for Intelligent Transportation Collaborative Perception
Authors: Pang Yafeng , Zhu Xingyi , He Tianyiyi , Liu Shuainian , Zhang Zixuan , Lv Qiaoya , Yi Peng , Lee Chengkuo 
Published: July 2024

AbstractCollaborative perception between a vehicle and the road has the potential to enhance the limited perception capability of autonomous driving technologies. With this background, self‐powered vehicle‐road integrated electronics (SVRIE) with a multilevel fractal structure is designed to play a dual role, including a SVRIE device integrated into vehicle tires and a SVRIE array embedded into a road surface. The pressure sensing capability and anti‐crosstalk performance of the SVRIE array are characterized separately to validate the feasibility of applying the SVRIE in a cooperative vehicle‐infrastructure system. It is demonstrated that the SVRIE based on the multi‐layered fractal structure exhibits maximum performance in collaborative sensing and interaction between vehicles and road information, such as vehicle motion, road surface condition, and tire life cycle health monitoring. Traditional data analysis methods are often of questionable accuracy. Therefore, a convolutional neural network is used to classify the vehicle and road conditions with accuracy of at least 88.3%. The transfer learning model is constructed to enhance the road surface identification capabilities with 100% accuracy. The accuracies of the vehicle tire motion recognition and tire health monitoring are 97% and 99%, respectively. This work provides new ideas for collaborative perception between vehicles and roadsides.
Recent Advances on Carbon‐Based Metal‐Free Electrocatalysts for Energy and Chemical Conversions
Authors: Zhai Qingfeng , Huang Hetaishan , Lawson Tom , Xia Zhenhai , Giusto Paolo , Antonietti Markus , Jaroniec Mietek , Chhowalla Manish , Baek Jong‐Beom , Liu Yun , Qiao Shizhang , Dai Liming 
Published: July 2024

AbstractOver the last decade, carbon‐based metal‐free electrocatalysts (C‐MFECs) have become important in electrocatalysis. This field is started thanks to the initial discovery that nitrogen atom doped carbon can function as a metal‐free electrode in alkaline fuel cells. A wide variety of metal‐free carbon nanomaterials, including 0D carbon dots, 1D carbon nanotubes, 2D graphene, and 3D porous carbons, has demonstrated high electrocatalytic performance across a variety of applications. These include clean energy generation and storage, green chemistry, and environmental remediation. The wide applicability of C‐MFECs is facilitated by effective synthetic approaches, e.g., heteroatom doping, and physical/chemical modification. These methods enable the creation of catalysts with electrocatalytic properties useful for sustainable energy transformation and storage (e.g., fuel cells, Zn‐air batteries, Li‐O2 batteries, dye‐sensitized solar cells), green chemical production (e.g., H2O2, NH3, and urea), and environmental remediation (e.g., wastewater treatment, and CO2 conversion). Furthermore, significant advances in the theoretical study of C‐MFECs via advanced computational modeling and machine learning techniques have been achieved, revealing the charge transfer mechanism for rational design and development of highly efficient catalysts. This review offers a timely overview of recent progress in the development of C‐MFECs, addressing material syntheses, theoretical advances, potential applications, challenges and future directions.